Trial · NCT05549934
Ritlecitinib for Cicatricial Alopecia
NCT05549934, Phase 2, Completed, Emma Guttman
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Ritlecitinib for Cicatricial Alopecia. Trials, record NCT05549934. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05549934
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Ritlecitinib for Cicatricial Alopecia
- NCT number
- NCT05549934
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 50 participants, actual
- Lead sponsor
- Emma Guttman
- Conditions
- Cicatricial Alopecia
- Interventions
- PF-06651600
- First posted
- 2022-09-22
- Last updated
- 2026-07-15
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Ct Values of mRNA Levels of CCL5 Gene | Baseline to Week 24 | Log-fold Changes in mRNA Levels of CCL5 gene expression in skin biopsies quantified by normalized Ct values obtained by quantitative real-time PCR assay, measured at baseline and week 24. The unit of the outcome is called Ct value and it represents the number of amplification cycles to reach a level of fluorescence in the experiment. The Ct value is directly associated to the level of expression of a gene |
| Primary | Number of Treatment-Emergent Adverse Events | Week 48 | The adverse event will be described and categorized as Treatment-emergent, Serious, abnormal in vital signals, and abnormalities in laboratory parameters. |
| Secondary | Percent Change in the Frontal Fibrosis Alopecia Severity Index (FFASI) | Baseline, Week 24, and Week 48 | The Frontal Fibrosis Alopecia Severity Index utilizes clinical images of the entire hairline from a total score of 0-84, with higher score indicating more severity. Percent change in FFASI at Week 24 and Week 48 as compared to baseline. |
| Secondary | Percent Change in the Lichen Planopilaris Activity Index (LPPAI) | Baseline, Week 24 and Week 48 | The Lichen Planopilaris Activity Index is a numeric composite index that aggregates symptoms and signs of pruritus, pain, burning, scalp erythema , perifollicular erythema, perifollicular scale , pull test and spreading. Symptoms and signs are measured in a 4-point scale (0-absent, 1-mild, 2-moderate and 3-severe). Full range from 0-10, higher score indicates more severity. Percent change in the LPPAI at Week 24 and Week 48 as compared to baseline. |
| Secondary | Percentage Change From Baseline in Change in Central Hair Loss Grade (CHLG) | Baseline, Week 24 and Week 48 | Percent change in Central Hair Loss Grade (CHLG) is an ordinal photographic outcome derived from a validated central scalp alopecia photographic scale to capture the pattern and severity of central hair loss. The scale uses standardized photographs and grades severity from 0 to 5, with 0 representing no hair loss, grades 1 and 2 representing early hair loss, and grades 3 to 5 representing probable CCCA with increasing severity. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05549934
GET https://conductscience.org/api/trials/v1/NCT05549934/registered